Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2007

01-12-2007 | Short communication

Is breast cancer advocacy distorting the cancer budget to the disadvantage of other tumours?

Author: Jim Cassidy

Published in: Breast Cancer Research | Special Issue 2/2007

Login to get access

Excerpt

Cancer is a common disease in all Western nations. Current estimates are that about one in three will develop cancer and about one in four will die from the disease. The ageing population means that this problem is likely to become even more prevalent. In contrast, it is hoped that the impact of screening and early detection of disease is that we will see more cancers at an earlier and hence more curable stage in their evolution. …
Metadata
Title
Is breast cancer advocacy distorting the cancer budget to the disadvantage of other tumours?
Author
Jim Cassidy
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1804

Other articles of this Special Issue 2/2007

Breast Cancer Research 2/2007 Go to the issue

Short communication

Why patient representation might harm science?

Short communication

Short-term presurgical treatment for all?

Short communication

Clinical outcomes: to be a surrogate or not to be ...?

Short communication

Why patient recorded outcomes should be mandatory in and outside clinical trials to guide management of patients with metastatic breast cancer

Section introduction

Introduction to sessions on Personalising treatment

Short communication

Oestrogen is bad for patients with breast cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits